Neurogene Past Earnings Performance
Past criteria checks 0/6
Neurogene has been growing earnings at an average annual rate of 84.9%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 150.2% per year.
Key information
84.9%
Earnings growth rate
85.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 150.2% |
| Return on equity | -38.7% |
| Net Margin | -354.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How Neurogene makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1 | -3 | 19 | 0 |
| 30 Jun 24 | 1 | 2 | 17 | 0 |
| 31 Mar 24 | 0 | 9 | 14 | 0 |
| 31 Dec 23 | 0 | 14 | 11 | 0 |
| 30 Sep 23 | 0 | -51 | 11 | 0 |
| 30 Jun 23 | 0 | -49 | 9 | -26 |
| 31 Mar 23 | 0 | -52 | 9 | -13 |
| 31 Dec 22 | 0 | -55 | 9 | 0 |
Quality Earnings: NGNE is currently unprofitable.
Growing Profit Margin: NGNE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if NGNE's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare NGNE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NGNE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: NGNE has a negative Return on Equity (-38.75%), as it is currently unprofitable.